STING1 and cancer: Thus, although the inability of DMXAA to activate human STING provided an obvious reason for failure of DMXAA in human cancer trials [20], [21], our results nevertheless suggest that vascular disruption might not occur in either primary or metastatic human NSCLC if human STING agonists were administered.